Antibodies Archives

cell medimmune influenza a antibody biotech

News and Trends 21 Jul 2016

‘Winner Antibody’ holds promise as universal Influenza A Vaccine

MedImmune and Humabs have reasons to be happy. Their candidate for an Influenza A vaccine has made it into well-known journal, Cell, boasting a unique affinity to the virus with multiple mechanisms to stop infection. The promising candidate is MEDI8852, an antibody initially developed by Humabs (Switzerland). It targets Influenza A virus (the group of viruses known as avian flu), […]

July 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

leo pharma astrazeneca dermatology biologics

News and Trends 4 Jul 2016

Danish Pharma enters in the Biologics arena with Antibody Buy-out

Leo Pharma is acquiring rights to two of AstraZeneca‘s candidates. The targeted indications are atopic dermatitis and psoriasis – autoimmune conditions getting more and more attention. Based near Copenhagen (Denmark), Leo Pharma specializes in dermatological therapies – particularly topical treatments. The company is not shy about its acquisitions, having entered a €675M deal to buy Japanese […]

July 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

venomab recombinant antivenom laustsen refresh

News and Trends 23 Jun 2016

‘Snake-bite Jesus’ pitched at Labiotech Refresh

VenomAb made quite an impression at the Startup Battle of Labiotech Refresh. Want to know what makes a biotech audience gasp unanimously? Then take a look at VenomAb’s pitch… We had Andreas Laustsen, founder of VenomAb, pitch his startup’s mission to bring antivenoms out of the 1900s into the modern age of biotech. The idea really captured […]

June 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

imab ganymed gastroesophegal cancer asco

News and Trends 17 May 2016

‘Ideal’ German Antibodies have promising data for Gastro Cancer

Ganymed is presenting promising results of its phase II trial in gastroesophageal cancer at the ASCO Annual meeting 2016 in Chicago, one of the leading Oncology conferences worldwide. Based in Mainz (Germany), Ganymed is a Biopharma developing immunotherapies to tackle cancer, having joined forces with BioNTech (Germany’s larget private Biotech) 2 years ago to create […]

May 17, 2016 - 2 minutesmins - By Denise Neves Gameiro

Neovacs lupus erythmatosis kinoid cytokine world day biotech therapy

News and Trends 10 May 2016

Today is World Lupus Day! Meet the people who are fighting this Rare disease

World Lupus Day is an initiative to increase the awareness around this disease which affects more than 5 million people worldwide. Last week in Paris, the biotech company Neovacs, which develops an innovative therapy against lupus, had gathered researchers, entrepreneurs and patients’ associations who are fighting the disease. I was there to meet them and […]

May 10, 2016 - 6 minutesmins - By Joachim Eeckhout

sanofi genzyme antibodies geel pompe leukemia

News and Trends 29 Apr 2016

Big Pharma invest massively in Biomanufacturing facilities

Sanofi is pumping €300M into its current manufacturing site in Belgium. This will support its antibody pipeline, with new laboratories of quality control and manufacturing sciences. Sanofi, France’s largest Pharma, seems to be betting more and more in biologics. Just a few years after buying Genzyme, it’s giving its subsidiary more prominence in their R&D. Now, […]

April 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 25 Mar 2016

Israeli Pharma gets FDA Approval for New Antibody against Severe Asthma

Teva (Israel) can now commercialize their intravenous drug (Cinqair) in the US, which will help adults with severe asthma. Based near Tel Aviv, Teva is the largest producer of generics, but it is also conducting its own biotech research. These include collaborations with Active Biotech (Sweden) for treatment of Huntington’s disease, and Heptares Therapeutics […]

March 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

humabs influenza antibody infectious cellclone medimmune

News and Trends 24 Mar 2016

Novel Antibody for Influenza gets FDA Fast-Track Approval

Humabs (Switzerland) has gotten some serious recognition for its antibody platform, as its candidates for Influenza have received FDA fast-track designation. A biologic therapy for Influenza A has been granted Fast Track Designation by the FDA, a ‘programme to accelerate the treatment commercialisation. The therapy is based on an antibody (MEDI8852) that was initially developed by […]

March 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

capella biosciences medicxi ventures advent life sciences osage university partners mabs monoclonal antibodies oncology autoimmune target biology

News and Trends 10 Mar 2016

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

Capella Biosciences (UK) is a life sciences start-up specializing in antibodies. It has just raised an additional €14.3M in a Series A round to develop their antibody pipeline to clinical stages. Capella started out in 2014 and based in London, defining its mission as developing therapeutic monoclonal antibodies for unmet medical needs. Back then, it received […]

March 10, 2016 - 2 minutesmins - By Denise Neves Gameiro

rheumatoid arthritis sirukumab galapagos johnson johnson JJ abbvie

News and Trends 3 Mar 2016

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

J&J has sold over 2 million of Galapagos‘ shares, which had been inherited from previous acquisitions, reducing its equity in this Belgian Biotech to below 5%. What’s wrong? Back in May, we talked about how J&J and AbbVie could be entering a fight for Galapagos’ filgotinib, a drug for rheumatoid arthritis (RA) that performed well […]

March 3, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 26 Feb 2016

A New Super-Antibody against Ebola has been Isolated

Humabs BioMed (Switzerland), in collaboration with institutional partners has succeeded in isolating new antibodies against the Ebola virus and turned them into a potential therapy against it. Humabs discovers monoclonal antibodies by doing blood analysis of survivors to given infectious diseases. For example, if one wants the cure for the flu, it looks into people […]

February 26, 2016 - 3 minutesmins - By Denise Neves Gameiro

osteoporosis vertebral column denosumab amgen ucb

News and Trends 22 Feb 2016

Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?

UCB (Belgium) has a monoclonal antibody candidate (romozumab) which has met its primary endpoints for a phase III Osteoporosis trial, FRAME in partnership with Amgen. The drug showed 75% improvement (compared to placebo) and few side effects. UCB in Brussels is developing immunotherapies for a range of chronic diseases, which has now gotten good phase III results for an […]

February 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us